Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Commission (EC) has granted marketing authorization in the European Union for ZALTRAP 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen
A panel of advisers to the European Union's health agency has again rejected Vivus Inc.'s weight...
The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralized marketing authorization for the medicine Ruvise.
European regulators approved the use of an imaging agent from Eli Lilly, which can help doctors diagnose Alzheimer's disease.
Genzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen®.
European Commission Approves Viread® for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in AdolescentsNovember 28, 2012 3:05 am | News | Comments
Gilead Sciences, Inc. has announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread® (tenofovir disoproxil fumarate).
A cancer treatment from Novartis received approval to be sold in Europe as a treatment for some patients with non-cancerous kidney tumors from a rare genetic disorder.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
AstraZeneca's Caprelsa (vandetanib) received approval from the European Commission for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease, the company reported Tuesday.
Roche announced Monday that the European Commission approved Zelboraf (vemurafenib) as a monotherapy for the treatment of adults with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Genzyme has announced that the EMA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme(R).
Basilea Pharmaceutica Ltd. today announced that it will apply in the second half of 2012 for approval of its antibiotic ceftobiprole in Europe.
With imports of pharmaceuticals to the U.S. on the rise and criticism of the U.S. Food and Drug Administration (FDA) that it has not inspected foreign plants with any regularity. The FDA is clearly on the defensive.
Novartis AG said Monday the European Commission has approved Rasitrio, a blood pressure treatment that combines three drugs into one pill.
ONGLYZA Approved for Use in Europe as Combination Therapy With Insulin in Adults With Type 2 DiabetesNovember 28, 2011 3:23 am | News | Comments
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA(R)(saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.
The European Commission said Thursday that pharmaceutical companies must develop more-effective medications against multi-drug resistant bacteria.
Pfizer Receives EU Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal DiseaseOctober 27, 2011 4:19 am | News | Comments
Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine 13-valent, adsorbed), for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.
Drug developer Ironwood Pharmaceuticals Inc. said Thursday that its partner Almirall SA has asked European Union regulators to approve its experimental drug linaclotide as a treatment for irritable bowel syndrome.
Eli Lilly announced Monday that EU regulators issued a positive opinion for the use of Alimta (pemetrexed) as continuation maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).
Bayer announced Friday that European regulators recommended expanding approval of Xarelto (rivaroxaban) to include use for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF).
WuXi AppTec announced today that its Bioanalytical Services (BAS) unit had received a certificate of Good Laboratory Practice (GLP) from the Organization for Economic Cooperation and Development (OECD) and the European Union (EU).